Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : 8-Methoxycoronaridine HCl
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
MINDCURE Achieves Key Development Milestone for Novel Ibogaine Program
Details : The filing of patent representing, novel, non-racemic ibogaine program, MC-808, an atypical psychedelic substance for use in treating a range of central nervous system disorders.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 02, 2022
Lead Product(s) : 8-Methoxycoronaridine HCl
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable